SHR-7787 combined with other anti-cancer drugs for malignant solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 study gives participants SHR-7787 together with one of several other anti-tumor agents (for example SHR-1316, SHR-4849, etoposide, or carboplatin) to see how the combinations perform. Eligible patients must have histologically or cytologically confirmed unresectable malignant solid tumors, at least one measurable lesion per RECIST 1.1, and ECOG performance status 0–1. Participants are monitored for safety, tolerability, and anti-tumor activity with regular imaging and clinical assessments. The trial requires adequate organ function and a minimum life expectancy of three months.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to understand and voluntarily agrees to participate by giving written informed consent for the study;
2. Patients with histologically or cytologically confirmed unresectable solid tumors;
3. At least one measurable lesion was identified per RECIST 1.1;
4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1;
5. Adequate organ functions as defined per protocol;
6. Minimum life expectancy of 3 months.

Exclusion Criteria:

1. Patients with known active central nervous system (CNS) metastases;
2. History of other malignancy within the past 5 years, with exceptions defined in the protocol;
3. Patients with uncontrolled cancer pain;
4. Patients with serious cardiovascular and/or cerebrovascular diseases;
5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion;
6. Patients with Severe infections within 4 weeks prior to the first dose;
7. Active pulmonary tuberculosis infection;
8. History of immunodeficiency;
9. History of autoimmune diseases;
10. The adverse events of previous antineoplastic therapy did not recover to CTCAE≤ grade 1;
11. Pregnant or nursing women, or planned to become pregnant during the study period;
12. Known allergic to any component of investigational drugs.

Where it's running

• Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
  Wuhan, Hubei, China Recruiting
• Shanghai Pulmonary Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Xianhua Qiu
• Email: xianhua.qiu@hengrui.com
• Phone: +86-0518-82342973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• TAK-505 treatment for adults with advanced solid tumors

  This trial will test TAK-505, an experimental drug, in adults with locally advanced or metastatic solid tumors (such as stomach, colorectal, non-small cell lung, and head and neck cancers) who have limited standard treatment options.

  Recruiting at 13 sites Phase 1/2 Takeda · Orange, California and 14 other locations · NCT07436728

• SHR-4298 Injection for Malignant Solid Tumors: a Phase I/II study

  This study tests SHR-4298 injections in adults with advanced solid tumors to see if it is safe, tolerable, and has signs of activity.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07229612

• SHR-4849 combined with other cancer drugs for malignant solid tumors

  This study will test whether adding SHR-4849 to other cancer drugs is safe and can help adults with malignant solid tumors.

  Recruiting Phase 2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Jinan, Shandong · NCT07028281

• JCXH-211 injections with anti-PD-1 therapy for malignant solid tumors

  This study tests whether injecting JCXH-211 directly into tumors, together with an anti-PD-1 medicine, is safe and tolerable in adults with malignant solid tumors.

  Recruiting Phase 1/2 Immorna Biotherapeutics, Inc. · Guangzhou, Guangdong · NCT06781125

• Evaluating SHR-1681 for patients with advanced solid tumors

  This study is testing a new injection called SHR-1681 to see if it can safely help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Phase 1/2 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Shanghai, Shanghai Municipality · NCT06737731

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.